Phone 088 97 29 430
The MLL/AF4 fusion gene, remains to be a high risk leukaemia, particularly in infants, accounting for >50% of the acute lymphoblastic cases. This fusion disrupts normal hematopoiesis and cell division.
This project aims to try an improve the therapy for this aggressive leukaemia. Using small interfering RNA (siRNA) targeted against the unique fingerprint of the fusion, we can disrupt the pathways that are required for these cells to maintain their leukemic properties. This project also aims to look at whether we can improve the efficacy and reduce toxicities by delivering the siRNA in lipid nano particles (LNPs) to the cells.